Fierce Biotech May 3, 2024
Welcome to this week’s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.
BridgeBio’s oncology team takes the reins of new spinout
BridgeBio Oncology Therapeutics
With BridgeBio’s attention squarely on seeing acoramidis through regulatory approval, the company is slicing off its oncology unit as a standalone company.
Leaders of the existing unit are joining the move, with oncology R&D chief Eli Wallace, Ph.D., named as CEO. Pedro Beltran, Ph.D., head of biology, will be the spinout’s CSO. BridgeBio Oncology Therapeutics—a name that clearly prioritizes clarity over wit—will...
Today's Sponsors
Today's Sponsor